Mounjaro, the ‘King Kong’ of Obesity Drugs, Seeks Irish Reimbursement

Eli Lilly, the maker of the highly anticipated obesity medication Mounjaro, has officially applied to the HSE for its consideration for public patients in Ireland. This application follows Lilly’s previous announcement that Mounjaro would be available for private prescription in early 2025.

If successful, this reimbursement application could make Mounjaro accessible to eligible public healthcare recipients, potentially revolutionizing obesity treatment in Ireland.

New Obesity Treatments: A Cautious Optimism

Despite the excitement surrounding Mounjaro and a host of new obesity medications, Susie Birney, a leading campaigner with the Irish Coalition for People Living with Obesity, emphasizes that these treatments are not a quick fix. “It’s this sense of excitement building that there is something here that finally people can use. Because people who’ve tried to lose weight have done that all their life,” she observed.

Birney stresses the importance of individual responses to these long-term medications. “You still have to work with it, you still have to watch what you eat, you still have to walk,” she explains. “You have to choose the healthy options, it doesn’t work by itself. I think that’s the misconception, that it’s an easy quick fix for weight loss rather than actually treating a disease.”

Mounjaro’s Impressive Results

According to Eli Lilly’s clinical trials, Mounjaro’s key ingredient, tirzepatide, has demonstrated significant weight loss benefits compared to other established obesity medications. They reported an average weight loss of 20.2% for participants on tirzepatide versus 13.7% for those on semaglutide (found in drugs like Ozempic and Wegovy).

On average, Mounjaro users lost 22.8 kg, while those on semaglutide lost 15.0 kg.

Addressing Misinformation and Promoting Responsible Use

Birney also expresses concern about the recent RTÉ Investigates program revealing illegal sales of weight-loss drugs. She urges individuals to consult with healthcare professionals for advice on obesity treatments, emphasizing the distinction between those who need them medically and those who want them solely for weight loss.

“There’s those who need (these treatments) and those who want it and there’s a huge difference between them,” she said.

She also highlights the societal pressure to conform to unrealistic beauty standards, particularly prevalent during the festive season. “There’s this deep-rooted sense of ‘having any excess weight on you is wrong’. It is as if you have morally failed.”

Visit Irish Examiner for more details about Mounjaro’s development and its potential impact on the fight against obesity in Ireland.